Program Overview
This CE activity is designed to educate healthcare providers involved in the prevention and management of prostate cancer by presenting the most recent information applicable to clinical practice, with the ultimate goal of improving patient care. Dr. Matthew Smith focuses on recent clinical trials in castration-resistant prostate cancer and the efficacy and safety data outcomes as well as the role of germline and tumor genetic testing. This information will allow healthcare professionals to better manage their patients with prostate cancer. Dr. Smith also incorporates the importance of the multidisciplinary team in treating patients with prostate cancer.
Target Audience
Oncologists, primary care physicians, internists, nurses, PAs, NPs, pharmacists, and other healthcare providers involved in the management of patients with prostate cancer
Agenda
- A Discussion of Genetic Mutations & Biomarkers of Prostate Cancer for Early Detection & Diagnosis
- Analyzing the Safety & Efficacy of the Latest Pharmaceutical Treatments for Prostate Cancer
- Developing Tailored Treatment Regimens with the Healthcare Team to Achieve Desired Outcomes
Learning Objectives
- Discuss the efficacy and safety data from recent practice-changing clinical trials in castration-resistant prostate cancer
- Describe the role of germline and tumor genetic testing to inform management of prostate cancer
- Understand the role of the multidisciplinary healthcare team to achieve the best outcomes for patients with prostate cancer
Faculty
Matthew R. Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Matthew R. Smith, MD, PhD | Consultant/Advisor: Consultant/Advisor: Amgen; Astellas Pharma US; Bayer AG; Janssen Pharmaceuticals, Inc.; Eli Lilly and Company |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; and Emma Boring hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 0.5 AMA PRA Category 1 CreditTM.
AcademicCME designates this live material for a maximum of 0.5 CNE Contact Hour (Provider number P0491).
AcademicCME designates this continuing education activity for 0.5 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (JA4008190-0000-20-010-H04-P).
Financial Support
This activity has been supported by an independent educational grant from Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
